Cyrus Harmon, Director at Olema Pharmaceuticals, Inc. (OLMA), sold 30,000 shares at $12.05 ($379K) on 2023-10-31, disclosed to the SEC on 2023-11-02.
Scheduled sale ($379k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.05 | 25,000 | $301K | 79.4% |
| 2 | $15.64 | 5,000 | $78K | 20.6% |
| Total | $12.65 avg | 30,000 | $379K | 100% |
| Filing → |
| OLMA | SELL | 2026-01-16 | $102K | — | Filing → |
| OLMA | SELL | 2025-12-29 | $164K | — | Filing → |
| OLMA | SELL | 2025-09-18 | $285K | — | Filing → |